Oncozyme Pharma to present data
on a novel oral form of pentamidine
(Oral OCZ103) at the AASLD
2014 annual meeting.

Learn More >

OE_SiteWeb_BulleImage_AASLDmeeting

Oncozyme Pharma is involved in the development of liver-targeting therapeutic agents for the treatment of liver diseases.

Learn More >

OE_SiteWeb_BulleImage_2femmes

Oral OCZ103 can deliver therapeutically relevant concentrations of pentamidine
to the liver, while avoiding
IV-related dose-limiting toxicity.

Learn More >

OE_SiteWeb_BulleImage_Hommebleu